In ex vivo experiments, combination treatment including atezolizumab (anti-PD-L1 mAb) and tiragolumab (anti-TIGIT mAb) restored the functionality of TILs from colorectal cancer patients [151]. This evidence concerns the gene CD274 and colorectal cancer.